Loading clinical trials...
Loading clinical trials...
Study of Thalidomide With First-line Chemotherapy and as Maintenance Treatment of Advanced Nonsquamous NSCLC With Epidermal Growth Factor Receptor Wild-Type or Unknown Mutation Status: A Multicenter, Randomized, Prospective Clinical Trial
Conditions
Interventions
Thalidomide
pemetrexed
+2 more
Locations
1
China
Qilu hospital of Shandong University
Jinan, Shandong, China
Start Date
December 1, 2016
Primary Completion Date
December 1, 2020
Completion Date
November 1, 2021
Last Updated
June 5, 2019
NCT05098132
NCT07171606
NCT06752044
NCT05403385
NCT05000710
NCT05219162
Lead Sponsor
Qilu Hospital of Shandong University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions